Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Phase 2
Terminated
- Conditions
- Pancreatic Cancer
- Interventions
- Other: immunohistochemistry staining methodOther: laboratory biomarker analysis
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT00470535
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00403000
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2014-01-03
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00281736
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
Phase 1
Terminated
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT00258258
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- Interventions
- Procedure: adjuvant therapyProcedure: conventional surgeryProcedure: neoadjuvant therapy
- First Posted Date
- 2005-11-04
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 38
- Registration Number
- NCT00248495
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma
- Interventions
- Biological: rituximab
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 42
- Registration Number
- NCT00244985
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Fulvestrant in Treating Patients With Advanced Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00244998
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT00238225
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT00217516
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Fulvestrant in Treating Patients With Recurrent Prostate Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00217464
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States